JAK2 and lymphoid neoplasm: Additional extended molecular analysis, including NGS-based search for fusions using RNA from a formalin-fixed, paraffin-embedded bone marrow biopsy, identified a PCM1(36)-JAK2(11) rearrangement, subsequently confirmed by FISH and the presence of a t(8;9)(p22;p24) in conventional cytogenetics, resulting in a diagnosis of a myeloid/lymphoid neoplasm with PCM1-JAK2 rearrangement, a provisional entity newly incorporated into the update of the 4th Edition of the WHO classification.